Recent Updates
Recently added Catalysts
AGEN Positive Sentiment

Agenus to Participate in Rodman & Renshaw Virtual Fireside Chat

Key Takeaway: Agenus Inc. announced participation in a virtual fireside chat hosted by Rodman & Renshaw. The event is scheduled for November 5, 2026, featuring Robin Taylor and Zack Armen. The discussion will center on the development of botensilimab and other innovations in immuno-oncology.

Market Sentiment Analysis

POSITIVE FACTORS

  • Agenus is recognized as a leader in immuno-oncology.
  • Participation in a prominent virtual fireside chat.
  • Discussion will focus on promising developments.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+203%
120-day peak, hindsight
Typical move
5.5%
average across 3 past catalysts
Cash runway
~0 mo
High dilution risk
Lead asset
Balstilimab
Phase 3 · Colorectal Cancer

Full Press Release Details

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #IO--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that Robin Taylor, Chief Commercial Officer, and Zack Armen, Vice President of Corporate Development and Investor Relations, will participate in a virtual fireside chat hosted by Rodman & Renshaw on Thursday, November 5, 2026. The discussion will be moderated by Michael G. King, Jr., Senior Biotechnology Analyst and will focus on the development of botensilimab (BOT) and ba

Frequently Asked Questions

When is the fireside chat scheduled?

The fireside chat is scheduled for November 5, 2026.

Who will participate in the chat?

Robin Taylor and Zack Armen will participate.

What will the discussion focus on?

The discussion will focus on the development of botensilimab.

Who is moderating the event?

Michael G. King, Jr. will moderate the event.

Last updated: Nov 2, 2026